Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide

Oncoscience

Volumn 3, Issue 5-6, 2016, Pages 156-163

  Rios, Adan ^a   Hsu, Sigmund H ^a   Blanco, Angel ^b   Buryanek, Jamie ^a   Day, Arthur ^a   McGuire, Mary F ^c   Brown, Robert E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEMORIAL HERMANN HOSPITAL   (United States)

^c UNIVERSITY OF ST THOMAS   (United States)

Author keywords

Biomedical analytics; Glioblastoma; Morphoproteomics; Plerixafor; Preventative and targeted therapy

Indexed keywords

EID: 84978229813     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.311     Document Type: Article

References (28)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, et al. Radiotherapy plus concomitant and adjuvant tomozolomide for glioblastoma. N. Engl. J. Med. 2005; 352 (10): 987-986.
2. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 2010;120(3): 694-705. doi: 10.1172/JCI40283.
3. Jin DK., Shido K., Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, Hattori K, Zhang F, Hicklin DJ, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangyocytes. Nat. Med. 2006;12(5):557-567.
4. Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem. 2001; 276(17):14153-14160.
5. Brown RE. Morphogenomics and morphoporteomics: a role for anatomic pathology in personalized medicine. Arch Pathol. Lab. Med. 2009; 133(4):568-579.
6. Rosner M, Siegel N, Valli A, Fuchs C, Hengstschläger M. mTOR phosphorylated at S2448 binds to raptor and rictor. Amino Acids. 2010; 38 (10): 223-228.
7. Rosner M, Hengstschläger M. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sinl. Hum Mol Genet. 2008; 17(19):2934-2948.
8. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005; 280:40406-40416.
9. Sun H, McGuire MF, Zhang S, Brown RE. NUT Midline Carcinoma: Morphoproteomic Characterization with Genomic and Therapeutic Correlates. Ann Clin Lab Sci. 2015;45:692-701
10. Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, Arcella A, De Sanctis V, Giangaspero F, Enrici RM. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2012; 83(1):93-9. Epub 2011 Nov 11.
11. Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Tumor stromal derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res. 2006; 66 (18): 9054-9064.
12. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF 1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin. Cancer Res. 2011; 17 (8):20740-2080.
13. Ehteshman M, Min E, Issar NM, Kasl RA, Khan IS, Thompson RC. The role of the CXCR4 cell surface chemokine receptor in glioma biology. J Neurooncol.2013;113:153-162.
14. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455: 1061-8.
15. Hatse S, Princen K, Bridger G, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 2002;527(1-3):255-262.
16. Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, Fricker S, Bridger G, Dunbar CE, Hematti P. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in non-human primates. Blood. 2006; 107: 3772-3778.
17. Bozdag CS, Tekgunduz E, Altuntas F. The current status in hematopoietic stem cell mobilization. J. Clin. Apher. 2015; 30: 273-280.
18. Flomenberg N, DiPersio J, Calandra G. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol. 2005:114:198-205.
19. Leia PN, Green S, Filka E, Lai A, Mellinghoff IK. Cloughesy TF. Pilot study of pulse high-dose lapatinib in combination with temozolomide (TMZ) and radiotherapy (RT) for upfront treatment of glioblastoma (GBM). ASCO Annual Meeting. 2014;Abstract No:2045.
20. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A., et al. Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012; 2:458-71.
21. Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, Gera J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 2007; 67 (24):11712-11720.
22. Verreault M, Weppler SA, Stegeman A, Warburton C, Strutt D, Masin D, Bally MB. Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model. PLoS ONE. 2013; 8: e59597.
23. Hwang YP, Jeong HG. Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase C alpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signalregulated kinase/activator protein-1. Br. J. Pharmacol. 2010; 160(5):1195-2011.
24. Qu Y, Zhang J, Wu S, Li B, Liu S, Cheng J. SIRT1 promotes proliferation and inhibits apoptosis of human malignant glioma cell lines. Neurosci. Lett. 2012 Sep 13;525(2):168-72.
25. Amengual JE, Clark-Garvey S, Kalac M, Scotto L, Marchi E, Neylon E, Johannet P, Wei Y, Zain J, O'Connor OA. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood. 2013;122 (12): 2104-2113.
26. Liu H, Liu Y, Liu W, Zhang W, Xu J. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat. Commun. 2015;6:84-94.
27. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, Sarkar FH. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila). 2012;5(3):355-64.
28. Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Deyin X, Kowalski M, Mingari MC, Vianello F, et al. CXCL12/ CXCR4 blockade induces multimodal anti-tumor effects that prolong survival in an immunocompetent model of ovarian cancer. Cancer Res. 2011; 71: 5522-5534. doi:10.1158/0008-5472. CAN-10-3143.